The global weight-loss drug market, once dominated by Novo Nordisk, is undergoing a dramatic transformation. On Friday, the ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Experts say the growing use of weight loss drugs may be helping to reverse obesity trends. ABC News medical contributor Dr. John Brownstein breaks down the latest study. Eli Lilly says new ...

Just three days after the Pfizer news, Eli Lilly announced positive results from its Phase III trial of weight-loss drug ... with the drug being assessed for bot diabetes and obesity treatment.

The obesity drug price wars are finally starting. After being publicly lambasted for the high cost of their weight-loss shots, two of world’s biggest drugmakers — Eli Lilly & Co. and Novo ...

Pharmaceutical company Eli Lilly ... obesity and diabetes. Besides the good news of minimal side effects and impressive results, though, the pill has an extremely unfortunate quality: its name ...

LONDON, April 25 (Reuters Breakingviews) - The pecking order of the obesity drug market is shifting. Eli Lilly (LLY.N), opens new tab, the $815 billion maker of blockbuster weight-loss drugs ...